What was the primary driver of Cencora's (formerly AmerisourceBergen) revenue growth in the reported quarter?

The primary driver of Cencora's revenue growth was the completion of the merger with Bergen Brunswig Corporation in August 2001. This significantly expanded the company's scale and operations, particularly within the Pharmaceutical Distribution segment.

What is the company doing to manage the costs associated with the merger?

Cencora is actively pursuing integration initiatives, including consolidating its distribution network and streamlining administrative functions. These efforts are expected to result in significant annual synergies, estimated at approximately $150 million, and involve the closure of several distribution facilities.

How is the company managing its debt and liquidity?

The company has a combination of fixed-rate and variable-rate debt. As of June 30, 2002, it had approximately $1.2 billion in fixed-rate debt and $355 million in variable-rate debt. Cencora reported strong liquidity and believes its operating cash flow, combined with available credit facilities, is sufficient to meet its ongoing financial obligations and fund future growth.

Are there any significant legal or contingent liabilities that investors should be aware of?

The company is involved in various legal proceedings, including antitrust actions, environmental matters, and contract disputes. While Cencora does not believe the resolution of these matters will have a material adverse effect on its financial condition, investors should monitor ongoing developments as outlined in Note 8 of the filing.

COR 10-Q Quarterly Report Q3 FY2002 — Revenue, Net Income, EPS

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported significant year-over-year growth in its quarterly filing for the period ending June 29, 2002. This growth is largely attributed to the merger with Bergen Brunswig Corporation, which was completed in August 2001. The company's operating revenue more than doubled compared to the prior year's quarter, driven by the Pharmaceutical Distribution segment. Despite increased operating expenses and merger-related costs, the company demonstrated improved operating income and net income. Key financial metrics show a substantial increase in total assets and a corresponding increase in total liabilities and stockholders' equity. The company is actively managing its integration efforts, including facility consolidations and employee severance, which are expected to yield significant annual synergies. Management expressed confidence in its liquidity and capital resources, anticipating sufficient cash flow to meet its ongoing obligations and fund future growth.

Key Highlights

1Operating revenue surged by 192% to $10.3 billion for the quarter ended June 30, 2002, compared to $3.5 billion in the prior year, primarily due to the merger with Bergen Brunswig.
2Net income increased by 186% to $90.2 million for the quarter, compared to $31.5 million in the prior year.
3Diluted earnings per share (EPS) saw a 44% increase to $0.82 for the quarter, up from $0.57 in the prior year.
4The company is undertaking significant integration initiatives post-merger, including consolidating distribution facilities, which are projected to generate approximately $150 million in annual synergies.
5Total assets grew to $10.43 billion as of June 30, 2002, up from $10.29 billion at September 30, 2001, while total liabilities and stockholders' equity also increased.
6The Pharmaceutical Distribution segment remains the primary revenue driver, showing strong growth driven by increased prescription drug usage and higher pharmaceutical prices.
7The company reported strong liquidity and capital resources, with sufficient cash flow from operations and available credit facilities to meet its obligations and fund future growth.

Cencora, Inc. Quarterly Report for Q3 Ended Jun 30, 2002

Summary

Key Highlights

Frequently Asked Questions